UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Does Linezolid Cause Lactic Acidosis by Inhibiting Mitochondrial Protein Synthesis?

Clinical infectious diseases, 2005-06, Vol.40 (12), p.e113-e116

2005

Volltextzugriff (PDF)

Laboratory test of suspended sediment effects on short‐term survival and swimming performance of juvenile Atlantic sturgeon (Acipenser oxyrinchus oxyrinchus, Mitchill, 1815)

Journal of applied ichthyology, 2015-12, Vol.31 (6), p.984-990

2015

Volltextzugriff (PDF)

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67

Annals of oncology, 2009-12, Vol.20 (12), p.1971-1976

2009

Volltextzugriff (PDF)

Commentary on “Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.”

Urologic oncology, 2018-07, Vol.36 (7), p.345-345

2018

Volltextzugriff (PDF)

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Annals of oncology, 2018-10, Vol.29, p.viii326-viii327

2018

Volltextzugriff (PDF)

Novel bone-targeting agents in prostate cancer

Prostate cancer and prostatic diseases, 2014-06, Vol.17 (2), p.112-118

2014

Volltextzugriff (PDF)

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

Annals of oncology, 2016-10, Vol.27, p.vi567-vi567

2016

Volltextzugriff (PDF)

Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer

The Journal of urology, 2019-03, Vol.201 (3), p.441-441

Chang, Sam S

2019

Volltextzugriff (PDF)

918TiPEV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx)

Annals of oncology, 2016-10, Vol.27, p.vi249-vi249

2016

Volltextzugriff (PDF)

Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study

Annals of oncology, 2016-10, Vol.27, p.vi294-vi294

2016

Volltextzugriff (PDF)

Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.4594-4594

2011

Volltextzugriff (PDF)

Detection of estrogen receptor α and β in a relevant model of human invasive urinary bladder cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15160-e15160

2011

Volltextzugriff (PDF)

Defining “cisplatin ineligible” patients with metastatic bladder cancer

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.238-238

2011

Volltextzugriff (PDF)

Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma In-situ is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer

Urologic oncology, 2020-12, Vol.38 (12), p.896-897

2020

Volltextzugriff (PDF)

Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS194-TPS194

2011

Volltextzugriff (PDF)

Germ-line single nucleotide polymorphism (SNP) predictors of progression-free survival and overall survival in patients with advanced prostate cancer treated with androgen-deprivation therapy (ADT)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.51-51

2011

Volltextzugriff (PDF)

Androgen pathway constitutional polymorphism predictors of progression-free and overall survivals in advanced castrate-resistant prostate cancer (CRPC) patients treated with ketoconazole (KC)

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.54-54

2011

Volltextzugriff (PDF)

A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e15173-e15173

2011

Volltextzugriff (PDF)

Use of germ-line single nucleotide polymorphisms (SNPs) in drug transporters (ABCG2/ABCB1) and tubulin (TUBB4) to predict survival in patients with metastatic castrate-resistant prostate cancer (CRPC) receiving docetaxel

Journal of clinical oncology, 2011-03, Vol.29 (7_suppl), p.58-58

2011

Volltextzugriff (PDF)

Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4541-4541

2010

Volltextzugriff (PDF)

Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3043-3043

2010

Volltextzugriff (PDF)

Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 ( 177 Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS193-TPS193

2011

Volltextzugriff (PDF)

Prognostic and therapeutic significance of pelvic lymph node dissection (PLND) extent in high-grade localized prostate cancer (PCa) patients (pts) treated with prostatectomy

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e15046-e15046

2010

Volltextzugriff (PDF)

1 – 25 von 3.460

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.848)
Mit Volltextzugriff
(2.826)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.789)
Life Sciences & Biomedicine
(1.160)
Humans
(923)
Female
(528)
Physics
(513)
Physical Sciences
(498)
Male
(496)
Biological And Medical Sciences
(379)
Animals
(333)
Adult
(326)
Middle Aged
(309)
Medical Sciences
(281)
Technology
(253)
Aged
(224)
Oncology
(149)
Fundamental And Applied Biological Sciences. Psychology
(132)
Materials Science
(126)
Adolescent
(124)
Physics, Particles & Fields
(118)
Neurosciences & Neurology
(112)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Does Linezolid Cause Lactic Acidosis by Inhibiting Mitochondrial Protein Synthesis?

Laboratory test of suspended sediment effects on short‐term survival and swimming performance of juvenile Atlantic sturgeon (Acipenser oxyrinchus oxyrinchus, Mitchill, 1815)

A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate-resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67

Commentary on “Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.”

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Novel bone-targeting agents in prostate cancer

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer

Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study

Re: Assessing Cancer Progression and Stable Disease after Neoadjuvant Chemotherapy for Organ-Confined Muscle-Invasive Bladder Cancer

918TiPEV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx)

Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study

Prognositic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer

Detection of estrogen receptor α and β in a relevant model of human invasive urinary bladder cancer

Defining “cisplatin ineligible” patients with metastatic bladder cancer

Extraction-Free Comprehensive Transcriptome Sequencing of Carcinoma In-situ is Highly Feasible and Insightful in Non-Muscle Invasive Bladder Cancer

Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors

Germ-line single nucleotide polymorphism (SNP) predictors of progression-free survival and overall survival in patients with advanced prostate cancer treated with androgen-deprivation therapy (ADT)

Androgen pathway constitutional polymorphism predictors of progression-free and overall survivals in advanced castrate-resistant prostate cancer (CRPC) patients treated with ketoconazole (KC)

A phase II trial of neoadjuvant cisplatin (C), gemcitabine (G), and sunitinib (S) in muscle-invasive urothelial carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 trial

Use of germ-line single nucleotide polymorphisms (SNPs) in drug transporters (ABCG2/ABCB1) and tubulin (TUBB4) to predict survival in patients with metastatic castrate-resistant prostate cancer (CRPC) receiving docetaxel

Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC)

Phase I study of sorafenib (S) with bevacizumab (B) and paclitaxel (P) in patients (pts) with refractory solid tumors

Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 ( 177 Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial

Prognostic and therapeutic significance of pelvic lymph node dissection (PLND) extent in high-grade localized prostate cancer (PCa) patients (pts) treated with prostatectomy

Suchergebnisse filtern